P.-Y. Shi

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

The paper shows the N501Y spike mutation in SARS-CoV-2 enhances viral transmission in hamsters and human airway cells by increasing receptor binding affinity.

This study evaluates the protective efficacy of modified miniproteins against SARS-CoV-2 in mice, showing reduced viral burden and prevention of lung disease.

A single dose of the VSV-vectored vaccine ConVac expressing SARS-CoV-2 S1 subunit protects hamsters from weight loss and viral replication after SARS-CoV-2 challenge.

The paper evaluates the neutralization effect of BNT162b2 vaccine-elicited sera against SARS-CoV-2 variants with specific spike mutations.

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

This paper develops a trans-complementation system to produce single-round infectious SARS-CoV-2 at BSL-2 labs, enabling safe high-throughput testing without full viral replication.

The paper assesses the neutralizing activity of BNT162b2 vaccine-elicited sera against N501Y and Y501 SARS-CoV-2 variants, finding equivalent neutralizing titers.

This study evaluates SARS-CoV-2 susceptibility in cell lines used for influenza and other virus diagnosis, finding that some are permissive while others are not, with MDCK cells being insusceptible due to low ACE2 expression.

This paper identifies a cyclic phosphoramidate prodrug that shows anti-dengue activity in vitro and in vivo but is suspended due to toxicity concerns.

This study shows SARS-CoV-2 infects human engineered heart tissues, causing myocarditis-like features, and identifies ACE2 and proteases as entry factors.

This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.

The paper identifies JIB-04 as a broad-spectrum antiviral that inhibits SARS-CoV-2 replication and coronavirus pathogenesis in vitro and in vivo.

This study examines how SARS-CoV-2 induces antiviral host responses, showing differences by viral load, age, and sex in gene expression profiles from infected individuals.

This study shows the D614G mutation in SARS-CoV-2 increases viral replication and upper respiratory tract viral loads but does not reduce vaccine efficacy or antibody neutralization.

This paper develops a PCR-based SARS-CoV-2 replicon system for antiviral screening, showing robust replication and inhibition by remdesivir.

This study investigates how nucleotide analogs like Remdesivir affect SARS-CoV-2 polymerase activity using single-molecule techniques, revealing backtracking rather than termination and evasion of ddhCTP.

This study identifies four mutations in Zika virus that reversed prior mutations, restoring fitness for urban transmission and increasing epidemic risk before the virus spread to the Americas.

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

This paper develops a high-throughput fluorescence-based assay to measure SARS-CoV-2 neutralizing antibodies, showing comparable results to the gold standard plaque reduction neutralizing assay.

The paper identifies TOP3B as essential for replication of positive-sense RNA viruses, including SARS-CoV-2, suggesting it as a potential antiviral target.

This study identifies the role of N-linked glycosylation in ZIKV E protein function across mosquito and human cells using a mutant library.